Nodosome Inhibition as a Novel Broad-Spectrum Antiviral Strategy against Arboviruses, Enteroviruses, and SARS-CoV-2
In the present report, we describe two small molecules with broad-spectrum antiviral activity. These drugs block the formation of the nodosome. The studies were prompted by the observation that infection of human fetal brain cells with Zika virus (ZIKV) induces the expression of nucleotide-binding oligomerization domain-containing protein 2 (NOD2), a host factor that was found to promote ZIKV replication and spread. A drug that targets NOD2 was shown to have potent broad-spectrum antiviral activity against other flaviviruses, alphaviruses, enteroviruses, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19). Another drug that inhibits receptor-interacting serine/threonine protein kinase 2 (RIPK2), which functions downstream of NOD2, also decreased the replication of these pathogenic RNA viruses. The antiviral effect of this drug was particularly potent against enteroviruses. The broad-spectrum action of nodosome-targeting drugs is mediated in part by the enhancement of the interferon response. Together, these results suggest that further preclinical investigation of nodosome inhibitors as potential broad-spectrum antivirals is warranted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:65 |
|---|---|
| Enthalten in: |
Antimicrobial agents and chemotherapy - 65(2021), 8 vom: 16. Juli, Seite e0049121 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Limonta, Daniel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral |
|---|
| Anmerkungen: |
Date Completed 22.07.2021 Date Revised 17.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1128/AAC.00491-21 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325527199 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325527199 | ||
| 003 | DE-627 | ||
| 005 | 20231225192630.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/AAC.00491-21 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1085.xml |
| 035 | |a (DE-627)NLM325527199 | ||
| 035 | |a (NLM)34001511 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Limonta, Daniel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nodosome Inhibition as a Novel Broad-Spectrum Antiviral Strategy against Arboviruses, Enteroviruses, and SARS-CoV-2 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.07.2021 | ||
| 500 | |a Date Revised 17.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In the present report, we describe two small molecules with broad-spectrum antiviral activity. These drugs block the formation of the nodosome. The studies were prompted by the observation that infection of human fetal brain cells with Zika virus (ZIKV) induces the expression of nucleotide-binding oligomerization domain-containing protein 2 (NOD2), a host factor that was found to promote ZIKV replication and spread. A drug that targets NOD2 was shown to have potent broad-spectrum antiviral activity against other flaviviruses, alphaviruses, enteroviruses, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19). Another drug that inhibits receptor-interacting serine/threonine protein kinase 2 (RIPK2), which functions downstream of NOD2, also decreased the replication of these pathogenic RNA viruses. The antiviral effect of this drug was particularly potent against enteroviruses. The broad-spectrum action of nodosome-targeting drugs is mediated in part by the enhancement of the interferon response. Together, these results suggest that further preclinical investigation of nodosome inhibitors as potential broad-spectrum antivirals is warranted | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a NOD2 | |
| 650 | 4 | |a RIPK2 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antiviral | |
| 650 | 4 | |a arbovirus | |
| 650 | 4 | |a broad spectrum | |
| 650 | 4 | |a coxsackievirus | |
| 650 | 4 | |a interferon | |
| 650 | 4 | |a nodosome | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Dyna-Dagman, Lovely |e verfasserin |4 aut | |
| 700 | 1 | |a Branton, William |e verfasserin |4 aut | |
| 700 | 1 | |a Mancinelli, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Makio, Tadashi |e verfasserin |4 aut | |
| 700 | 1 | |a Wozniak, Richard W |e verfasserin |4 aut | |
| 700 | 1 | |a Power, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Hobman, Tom C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antimicrobial agents and chemotherapy |d 1972 |g 65(2021), 8 vom: 16. Juli, Seite e0049121 |w (DE-627)NLM000026506 |x 1098-6596 |7 nnns |
| 773 | 1 | 8 | |g volume:65 |g year:2021 |g number:8 |g day:16 |g month:07 |g pages:e0049121 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/AAC.00491-21 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 65 |j 2021 |e 8 |b 16 |c 07 |h e0049121 | ||